XML 37 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Summary of Significant Accounting Policies (Details)
3 Months Ended 12 Months Ended
Mar. 29, 2019
Mar. 31, 2018
Mar. 31, 2017
Jan. 03, 2020
USD ($)
segment
product
Dec. 28, 2018
USD ($)
Dec. 29, 2017
USD ($)
Organization And Summary Of Significant Policies [Line Items]            
Number of operating segments | segment       1    
Impairment charge on goodwill | $       $ 0    
Percent discount for prompt payment       2.00%    
Discount expected to be earned       100.00%    
Medicare Part D Funding Mandate 70.00% 50.00% 50.00%      
Materials in inventory balances | $       $ 0 $ 0  
Advertising expense | $       $ 17,900,000 $ 14,800,000 $ 8,600,000
Maximum            
Organization And Summary Of Significant Policies [Line Items]            
Estimated useful lives       15 years    
Collaborative Arrangement with GlaxoSmithKline            
Organization And Summary Of Significant Policies [Line Items]            
Cost of goods sold is related to product       3.00%    
Resulting From Discovery Efforts            
Organization And Summary Of Significant Policies [Line Items]            
Number of products that entered in the commercial marketplace | product       4    
Products Derived from Cabozantinib            
Organization And Summary Of Significant Policies [Line Items]            
Number of products that entered in the commercial marketplace | product       2    
Products Derived From Other Compounds            
Organization And Summary Of Significant Policies [Line Items]            
Number of products that entered in the commercial marketplace | product       2